浏览全部资源
扫码关注微信
1.华中科技大学同济医学院医药卫生管理学院,武汉 430030
2.中南财经政法大学公共管理学院,武汉 430073
Published:30 May 2023,
Received:19 October 2022,
Revised:18 March 2023,
扫 描 看 全 文
彭瑾,蒋俊男,邱增辉等.国家医保谈判药品在浙江省三级医疗机构的落地实践 Δ[J].中国药房,2023,34(10):1159-1164.
PENG Jin,JIANG Junnan,QIU Zenghui,et al.Landing practices of national medical insurance negotiated drugs in tertiary medical institutions of Zhejiang province[J].ZHONGGUO YAOFANG,2023,34(10):1159-1164.
彭瑾,蒋俊男,邱增辉等.国家医保谈判药品在浙江省三级医疗机构的落地实践 Δ[J].中国药房,2023,34(10):1159-1164. DOI: 10.6039/j.issn.1001-0408.2023.10.02.
PENG Jin,JIANG Junnan,QIU Zenghui,et al.Landing practices of national medical insurance negotiated drugs in tertiary medical institutions of Zhejiang province[J].ZHONGGUO YAOFANG,2023,34(10):1159-1164. DOI: 10.6039/j.issn.1001-0408.2023.10.02.
目的
2
为我国国家医保谈判药品(简称“国谈药品”)在省级层面的落地提供参考和借鉴。
方法
2
通过查阅2021年1月-2022年3月国家医保局、浙江省医保局等官方网站公开发布的数据,结合政策文件,对浙江省各地市三级医疗机构数量、国谈药品实际配备情况、国谈药品可获得率、国谈药品品种配备率、医疗机构配备率等进行描述性分析;采用Spearman秩相关检验对浙江省三级医疗机构配备的国谈药品品种数与浙江省各地市人均可支配收入、配备国谈药品的三级医疗机构数、疾病诊断相关分组(DRG)实施时长等进行相关性分析。
结果
2
截至2022年第1季度,浙江省135家三级医疗机构共配备国谈药品261种,占2021版国谈药品目录(275种)的94.91%;醋酸戈舍瑞林缓释植入剂、沙库巴曲缬沙坦钠片、注射用阿替普酶等品种配备率较高,配备的国谈药品种类与浙江省城乡居民排名前10位的疾病死亡原因高度重合。杭州市的三级医疗机构配备种类最多,达230种,衢州市最低,仅为34种;舟山市的医疗机构配备率最高(100%),丽水市最低(57.14%)。国谈药品配备品种数与各地市人均可支配收入、配备国谈药品的三级医疗机构数量均呈正相关(
P
<0.01),与DRG的实施时长无明显相关性(
P
>0.05)。
结论
2
浙江省国谈药品的落地情况总体较好,国谈药品三级医疗机构配备率、药品品种配备率较高。建议国谈药品的省级落地需多方联动,政策制定部门应“松绑”“驱动”双管齐下,畅通药品进院链条;医保部门应完善 “双通道”管理机制,分担医疗机构用药压力;同时,还应完善多层次医疗保障体系,提高国谈药品医保报销水平。
OBJECTIVE
2
To provide reference for the subsequent landing of national medical insurance negotiated drugs (referred to as “national negotiated drugs”) at the provincial level.
METHODS
2
By reviewing the data publicly released by the official websites of National Healthcare Security Administration and the Healthcare Security Administration of Zhejiang Province, combined with policy documents, the descriptive analysis was conducted on the number of tertiary medical institutions, the actual allocation of national negotiated drugs, the availability rate of national negotiated drugs, the allocation rate of national negotiated drug varieties, and the allocation rate of medical institutions of various cities in Zhejiang province. The Spearman rank correlation test was used to analyze the correlation between the number of types of national negotiated drugs equipped in tertiary medical institutions in Zhejiang province and the per capita disposable income, the number of tertiary medical institutions equipped with national negotiated drugs, and the implementation time of disease diagnosis-related grouping (DRG) of various cities in Zhejiang province.
RESULTS
2
As of the first quarter of 2022, 135 tertiary medical institutions in Zhejiang province were equipped with a total of 261 types of national negotiated drugs, accounting for 94.91% of the 2021 edition of the National Negotiated Drugs Catalogue (275 types). The allocation rates of Goserelin acetate sustained-release implant, Sacubitril valsartan sodium tablets, Alteplase for injection and other varieties were at high level, and the types of national negotiated drugs equipped were highly coincident with the top 10 causes of death with disease of urban and rural residents in Zhejiang province. The tertiary medical institutions in Hangzhou had the most types of national negotiated drugs, with 230 types, while Quzhou had the lowest, with only 34 types; allocation rate of national negotiated drugs in medical institutions of Zhoushan was the highest (100%), while that of Lishui was the lowest (57.14%). The types of national negotiated drugs equipped were positively correlated with per capita disposable income in various cities and the number of tertiary medical institutions equipped with national negotiated drugs (
P
<0.01), and there was no significant correlation with the length of implementation of DRG (
P
>0.05).
CONCLUSIONS
2
The landing of national negotiated drugs in Zhejiang province is generally good, with a high rate of equipping tertiary medical institutions with national negotiated drugs and a high rate of equipping drug varieties. Therefore, it is recommended that the provincial implementation of national negotiated drugs should be multi-faceted, and policy-making departments should adopt a dual-channel of “unbundling” and “driving” to smooth the drug chain into hospitals. The health insurance sector should improve the “dual channel” management mechanism to share the pressure on hospitals to use drugs. At the same time, it should also improve the multi-level medical security system and raise the level of reimbursement of medical insurance for national negotiated drugs.
国家医保谈判药品落地实践双通道浙江疾病诊断相关分组
landing practicedual-channelZhejiangDRG
戴伟.用市场思维引导谈判药品落地[J].中国社会保障,2021(8):27.
檀朝明,黄悦康,汪茂艳,等.国谈药“双通道”闭环管理的南京实践与探索[J].中国医疗保险,2022(5):75-78.
谢金平,邵蓉.国家医保谈判药品省级落地管理典型模式研究[J].中国卫生经济,2020,39(6):42-46.
陈庆锋,康洽福,丁榕芳,等.医保谈判药品纳入特药药房统筹结算可行性研究:基于福建省省本级医保谈判药品管理实践[J].中国医疗保险,2019(4):51-56.
陈玲玲,徐伟,尚波波,等.国家谈判药品可获得性研究:基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,37(12):17-20.
张苗.广东:谈判药品如何“软着陆”[J].中国社会保障,2018(2):70-73.
梁冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,37(5):42-44,49.
袁惜方,尚培治,张冬儿,等.“双通道”模式下不同支付方式对医保预算的影响分析:以耐多药肺结核治疗为例[J].中国卫生经济,2022,41(5):32-35.
蒙文鑫,蒋蓉.江苏省国家谈判药品“双通道”管理政策比较研究[J].中国卫生政策研究,2022,15(7):38-44.
韩晓睿,丁锦希,李伟,等.国家谈判药品“双通道”的遴选标准与实施路径[J].世界临床药物,2021,42(9):717-724.
曹庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究:基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53-56,59.
陈一,丁锦希,陈烨,等.“双通道”框架下的DTP药房管理模式研究[J].世界临床药物,2021,42(9):725-733.
福建省医保中心.福建省医保局率先上线省级“双通道”电子处方流转服务[J].就业与保障,2021(23):11.
黄河清.全省进入医保费用线上支付时代[N].昆明日报,2022-07-05(4).
徐伟伟,胡振产.医保支付制度改革的“浙江范式”[J].卫生经济研究,2021,38(12):3-6,10.
胡哲南.我市“选缴保费法”为患者减负51亿元[N].金华日报,2022-09-13(A01).
叶龙杰.优化“双通道”机制 提高用药可及性[N].健康报,2022-09-02(5).
0
Views
13
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution